Sarepta Therapeutics Inc. reported its second patient death due to acute liver failure after receiving its gene therapy Elevidys for Duchenne muscular dystrophy. The death occurred three months after a teenage boy’s fatal reaction to the treatment, also targeting patients with this rare muscle disorder who are unable to walk.
Source: https://www.bloomberg.com/news/articles/2025-06-15/sarepta-reports-second-death-of-patient-using-its-gene-therapy